Outcomes of digoxin vs. beta-blocker in AF: report from ESC-EHRA EORP-AF Long-Term General Registry.

---

Copy For Citation

Ding W. Y., Boriani G., Marin F., Blomström-Lundqvist C., Potpara T. S., Fauchier L., ...More

European heart journal. Cardiovascular pharmacotherapy, vol.8, pp.372-382, 2022 (SCI-Expanded)

• Publication Type: Article / Article
• Volume: 8
• Publication Date: 2022
• Doi Number: 10.1093/ehjcvp/pvab076
• Journal Name: European heart journal. Cardiovascular pharmacotherapy
• Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, EMBASE, MEDLINE
• Page Numbers: pp.372-382
• Keywords: Atrial fibrillation, Digoxin, Beta blocker, Rate control, Mortality, Hospitalizations, Quality of life, Permanent AF, Heart failure, CKD, EORP-AF, Registry, HEART-FAILURE, INCREASED MORTALITY, RISK, METAANALYSIS, GUIDELINES, MANAGEMENT, EFFICACY, STROKE
• Hacettepe University Affiliated: Yes

Abstract

Aims The safety of digoxin therapy in atrial fibrillation (AF) remains ill-defined. We aimed to evaluate the effects of digoxin over beta-blocker therapy in AF.